LGND - Ligand Pharma's insider buying accelerates in 2021

Insider buying at Ligand Pharmaceuticals (LGND) has accelerated in 2021, the latest SEC filings submitted by the company indicate.Ligand Pharma CEO John Higgins, and COO, Matthew Foehr have purchased a net ~38.1K and ~5.2K of company shares for the year so far.The duo’s combined insider purchases at net ~43.3K shares implies ~41.7% of net insider purchases for the past six-month period indicating an acceleration of insider purchases.With 64.4% short interest, Ligand shares are continuing the four-day winning streak today with a rise of ~2.7% in value so far.However, Seeking Alpha contributor, The Value Investor, said in a neutral thesis on the stock, ‘with many parts uncertain’ Ligand Pharma ‘remains a show me story.’

For further details see:

Ligand Pharma’s insider buying accelerates in 2021